Literature DB >> 8597429

Behavioral, neurochemical, and immunological responses to CRF administration. Is CRF a mediator of stress?

C Song1, B Earley, B E Leonard.   

Abstract

The effect of subacute intracerebroventricular (icv 0.1, 0.5, and 1.0 microgram) administration of corticotropin-releasing factor (CRF) for 5 days on behavior, neurotransmitter concentrations, and immune functions was studied in rats. The results showed that CRF administration produced a dose-dependent increase in locomotor activity in the "open field" test compared with controls; rearing scores were also significantly increased. In the elevated plus maze apparatus, rats given 1.0 microgram CRF spent considerably less time on the open arms when compared with controls. Following 0.5 and 1.0 microgram of CRF infusion, the concentrations of noradrenaline (NA), dopamine (DA) and 5-hydroxy indole acetic acid (5-HIAA) were significantly increased in the hypothalamus. There was no significant change in the concentrations of neurotransmitters in the other brain regions. CRF administration also produced a dose-dependent increase in the levels of corticosterone in the serum. The immunological results clearly showed that subacute icv CRF administration caused a reduction of lymphocyte proliferation, a decrease in the percentage of lymphocytes, and an increase in neutrophil percentage in the differential white blood cell (WBC) count, a decrease in neutrophil phagocytosis, and elevated leucocyte adhesiveness/aggregation (LAA) compared with control animals. These results suggest that icv subacute administration of CRF has anxiogenic effects, increases biogenic amine concentrations in the hypothalamus, and changes in some aspects of immune functions that may reflect the stress-inducing properties of the peptide. These effects are time and dose dependent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8597429     DOI: 10.1111/j.1749-6632.1995.tb44670.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking in C57BL/6J mice independent of the HPA axis.

Authors:  Emily G Lowery; Marina Spanos; Montserrat Navarro; Angela M Lyons; Clyde W Hodge; Todd E Thiele
Journal:  Neuropsychopharmacology       Date:  2010-02-03       Impact factor: 7.853

2.  Anxiogenic effects of CGRP within the BNST may be mediated by CRF acting at BNST CRFR1 receptors.

Authors:  K S Sink; A Chung; K J Ressler; M Davis; D L Walker
Journal:  Behav Brain Res       Date:  2013-02-01       Impact factor: 3.332

Review 3.  Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome.

Authors:  Maria M Buckley; Siobhain M O'Mahony; Dervla O'Malley
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 4.  Innovative approaches for the treatment of depression: targeting the HPA axis.

Authors:  Fiona Thomson; Mark Craighead
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

5.  The effects of repeated intra-amygdala CRF injections on rat behavior and HPA axis function after stress.

Authors:  W M U Daniels; L Richter; D J Stein
Journal:  Metab Brain Dis       Date:  2004-06       Impact factor: 3.584

Review 6.  The Role of the Gut Microbiota in Dietary Interventions for Depression and Anxiety.

Authors:  Tracey L K Bear; Julie E Dalziel; Jane Coad; Nicole C Roy; Christine A Butts; Pramod K Gopal
Journal:  Adv Nutr       Date:  2020-07-01       Impact factor: 8.701

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.